PS
CYTK icon

Principal Securities’s Cytokinetics CYTK Stock Holding History

Principal Securities’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-13
Closed -$714 – 1825
2025
Q3 		$714 Buy
+13
New +$536 ﹤0.01% 3475
2024
Q4 		– Sell
-5
Closed -$264 – 3563
2024
Q3 		$264 Buy
5
+4
+400% +$223 ﹤0.01% 3342
2024
Q2 		$54 Hold
1
– – ﹤0.01% 3373
2024
Q1 		$70 Hold
1
– – ﹤0.01% 3293
2023
Q4 		$83 Buy
+1
New +$36 ﹤0.01% 3191

Other funds holding CYTK

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return

Principal Securities's CYTK Position: Q4 2025 in Review

Principal Securities sold out of Cytokinetics (CYTK) in Q4 2025, closing a stake of 13 shares — an estimated $714 sold.

Principal Securities first reported a position in CYTK in Q4 2023 and held it in 5 quarters. The position peaked at $714 in Q3 2025. 431 funds tracked by Wall St. Rank hold CYTK as of Q4 2025.

  • Principal Securities reported no remaining Cytokinetics position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 13 Cytokinetics shares in Q4 2025, an estimated $714.
  • Principal Securities first reported a position in Cytokinetics in Q4 2023 and held it in 5 quarters.
  • Principal Securities's Cytokinetics position peaked at $714 in Q3 2025.
  • 431 funds tracked by Wall St. Rank held Cytokinetics as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.